Efficacy and Safety of Dapagliflozin for the Hospital Management of Patients With Type 2 Diabetes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 250 participants.
Also called NCT05457933
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 250 participants
- Sponsor
- Registry
-
NCT05457933
-
- Other papers using this trial's data
- Dapagliflozin for inpatient hyperglycemia in cardiac surgery patients with type 2 diabetes: randomised controlled trial (Dapa-Hospital trial)
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- India
- Registry status
- Completed
Technical summary
Registry record NCT05457933. Randomized; no masking; primary purpose treatment. Start 2022-07-29 (actual); primary completion 2023-01-14 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Dapagliflozin for the Hospital Management of Patients With Type 2 Diabetes
- Condition
- Type2diabetes
- Condition
- Coronary Artery Disease
- Intervention (Drug)
- Dapagliflozin
- Intervention (Drug)
- Glargine
- Lead sponsor
- Medanta, The Medicity, India
Record details
- Record id
cardio:ct-nct05457933- Content hash
0857a27271e02f71f6ea4cd6da005b3824b901e2f4af11538a6bf583b226f5a1